Home > News


Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

EMA: First CAR-T cell medicine for mantle cell lymphoma

EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Tecartus (autologous anti-CD19-transduced CD3+ cells) for the treatment of adult patients with a rare cancer of white blood cells called mantle cell lymphoma (MCL) [...]

Find out why Viglya is your strategic partner in drug development.Read more